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Abstract 
The antineoplastic activity of HDAC inhibitors is an unquestionable property of these 
compounds, but recent studies in tumor cells have revealed the potential of HDAC inhibitors 
(e.g. suberoylanilide hydroxamic acid SAHA, valproic acid VPA) to cause acquisition of HDAC 
inhibitor resistance. We report that trichostatin A (TSA), an HDAC inhibitor structurally related 
to SAHA, causes the acquisition of multidrug resistance transporter-independent and irreversible 
3-fold resistance to TSA in MLH1-deficient (absent MLH1 protein expression) but not in 
MLH1-proficient (expressing MLH1 protein) HCT116 colon tumor cells. This MLH1-deficient 
subline selected for TSA resistance by stepwise exposures to increasing TSA concentrations 
exhibited failure in the accumulation of acetylated histones, in p21 induction, and in apoptosis 
activation. These are cellular responses normally seen in tumor cells treated with HDAC 
inhibitors. Whereas the absence of acetyl-histone accumulation did not correlate with altered 
HDAC activity, the absence of apoptosis correlated with reduced expression of (pro-apoptotic) 
Bax. This TSA-resistant subline was cross-resistant to SAHA and VPA but not to “classic” non-
HDAC inhibitor-type anticancer agents such as docetaxel and doxorubicin. These herein 
presented results expand on a previous study reporting HDAC inhibitor resistance acquisition by 
SAHA which was independent of the MLH1 expression status. Taken together, the present study 
identifies TSA, besides SAHA and VPA, as another potential causative of HDAC inhibitor 
resistance acquisition specifically in MLH1-deficient HCT116 colon tumor cells, and it reveals a 
possible function of MLH1 protein in protecting colon tumor cells from resistance acquisition 
by TSA. 
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Introduction 
Resistance to anticancer drugs is a relevant problem and limits the effectiveness of anticancer 
therapy. Drug resistance is multifactorial and multiple ways by which cancer cells can elude 
therapy have been described, including expression of efflux pumps, regulation of apoptosis, and 
drug detoxification. Acquired resistance is a particular problem, because tumors not only can 
become resistant to the drugs originally used to treat them, but may also become cross-resistant 
to other drugs with different mechanisms of action. Resistance development can occur with any 
chemotherapeutical agent and is not restricted to any specific tumor type. 
 We have previously shown that suberoylanilide hydroxamic acid (SAHA, vorinostat), a 
representative of the class of histone deacetylase (HDAC) inhibitors, can cause acquisition of 
irreversible and multidrug resistance-independent HDAC inhibitor-resistance in HCT116 colon 
tumor cells, with the corresponding losses of growth inhibition, of apoptosis, and of histone 
acetylation (1,2). HDAC inhibitors are a class of anticancer agents that act by epigenetically 
regulating gene expression through chromatin remodeling. HDAC inhibitors induce the 
acetylation of histones and many non-histone proteins involved in regulation of gene expression, 
cell migration, proliferation, cell cycle and cell death (3-7). 
 The observed SAHA-induced HDAC inhibitor resistance was found with HCT116 cells 
expressing MLH1 protein (MLH1-proficient) as well as in HCT116 cells lacking MLH1 
expression (MLH1-deficient) (1). MLH1 is one out of at least 5 proteins crucial to DNA 
mismatch repair (MMR) function, a mechanism involved in DNA damage surveillance, 
elimination of biosynthetic errors arising during replication, and prevention of recombination 
between non-identical DNA sequences (8-10). Loss of MMR is another cause of drug resistance, 
in particular with platinum-derived chemotherapeutics, due to the inability to detect the DNA 
damage and to induce cell cycle arrest and apoptosis (11). 
 Recent studies (12-14) have shown that MLH1 expression is positively affected by 
trichostatin A (TSA), one of the first selective HDAC inhibitor identified and often considered 
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as the model HDAC inhibitor (15). Furthermore, microsatellite instable (MSI) and HDAC-2-
mutated tumor cells showed absence of histone hyperacetylation in response to TSA (16) and 
resistance to TSA-induced apoptosis (17). TSA has also been shown to slow radiation-induced 
DNA damage repair process in part by suppressing BRCA1 gene expression (18) and to be 
genotoxic due to the hyperacetylation of centromers leading to aneuploidy and DNA strand 
breaks (19) and leading to chromosome missegregation and multinucleation (20). 
 Incited by this body of data, the present study was aimed at investigating (i) whether 
TSA, similar to SAHA, can cause HDAC inhibitor resistance in colon tumor cells, (ii) whether 
the MLH1 expression status is relevant for resistance acquisition by TSA, and (iii) whether 
TSA-resistant sublines are cross-resistant to “classic” anticancer agents. 
 
 
 
Materials and Methods 
Drugs and chemicals.  The HDAC inhibitors suberoylanilide hydroxamic acid (SAHA; Alexis 
Biochemicals, Lausen, Switzerland), trichostatin A (TSA), and valproic acid (VPA) were 
purchased (Sigma, Buchs, Switzerland), as were docetaxel, doxorubicin, and 6-thioguanine 
(Sigma). Temozolomide was a generous gift (Schering-Plough, Kenilworth, NJ). Stock solutions 
were prepared in DMSO (SAHA, temozolomide), in ethanol (docetaxel, TSA), or in H2O 
(doxorubicin, 6-thioguanine, VPA). All stock solutions were stored at -20°C. 
 
Cell culture and generation of TSA-resistant sublines.  The following cell lines were used. The 
parental HCT116 human colon tumor cell line (American Type Culture Collection; ATCC CCL 
247), which lacks expression of MLH1 protein due to a mutation in the coding region of the 
MLH1 gene and hence is deficient in DNA mismatch repair function; the MLH1-proficient HT-
29 colon tumor cell line and the (MLH1-proficient) HeLa cervical tumor cell line; a pair of the 
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quasi-isogenic MLH1-deficient HCT116ch2 cell line (complemented with chromosome 2) and 
the MLH1-proficient HCT116ch3 counterpart cell line (complemented with chromosome 3 
housing a wild-type copy of the MLH1 gene, thus rendering it MLH1-proficient), which were 
derived from the parental MLH1-deficient HCT116 cell line. The characteristics of the cell lines 
(e.g. chromosome complementation) and the culturing conditions have been described 
previously (1,21). When seeded sparsely on tissue culture plates, all the cell lines and sublines 
formed well-defined individual colonies. 
 Analogous to the protocol described previously (1), the following sublines, hereafter 
designated as HCT116/TSA, HT-29/TSA, HeLa/TSA, HCT116ch2/TSA, and HCT116ch3/TSA, 
were generated by stepwise exposures of the respective cell lines to increasing concentrations of 
TSA, starting with 50 nM TSA for HCT116, HCT116ch2, HCT116ch3, and HeLa or with 250 
nM TSA for HT-29. Basically, 200,000 cells were plated in culture flasks and treated with TSA 
after 24h. After another 48h, the medium was exchanged for TSA-free medium, followed by 
incubation to allow recovery of the surviving cells. These were harvested by trypsinization, 
transferred into flasks, and expanded to confluence. One fraction was stored at -80°C, the other 
(200,000 cells) was re-seeded in culture flasks and subjected to treatment with TSA 24h later, to 
medium exchange, to recovery and to harvesting as described. This protocol was repeated 7 
times for each cell line, except for the HT-29 cell line (5 times: at the subsequent step 6 but cells 
did not manage to expand further). For each cycle, the TSA concentration was incremented, 
resulting in a 40-fold total increment (last cycle: 2 M TSA) for each cell line, except for HeLa 
(20-fold) and HT-29 (4-fold). Further increases in the selection pressure beyond these TSA 
concentrations failed to produce sufficient surving cells for further cell culture expansion. 
 The principle of selection was clonal growth in the presence of increasing TSA 
concentrations, on the basis that cells are altered by chronic TSA exposure in a way they acquire 
new features in an irreversible fashion. The growth rates of the cell lines and the respective 
sublines were calculated from the doubling times from one passage to the subsequent, averaged 
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over a period of two months, and compared to one another. The level of resistance was 
determined right after the cells had been expanded to confluence after the last cycle by the 
clonogenic assay (these are the IC50 values presented throughout the paper) and was periodically 
monitored against the parental cell line. The level of resistance was stable over a period of five 
months even when cells were cultured in the absence of the selection pressure of TSA. 
 
Drug sensitivity and apoptosis assays.  Drug sensitivity was determined by the clonogenic assay 
as described previously (1,2). Apoptosis induced by TSA was assessed by immunoblot analysis 
(see below) on the basis of the proteolytic cleavage of the PARP-1 precursor. The reduction in 
the level of the 116 kD PARP-1 full-length precursor and the reciprocal accumulation of its 86 
kD cleaved fragment is a measure for ongoing apoptosis. 
 
Immunoblot analysis.  Cells grown to 70% confluence in 60 mm dishes were treated with TSA. 
Floating and adherent cells were collected by trypsinization 12h, 24h, 36h, and 48h after 
addition of 350 nM TSA. They were prepared for immunoblot analysis performed following 
standard protocols for PAGE gel electrophoresis. Twenty g protein was separated using SDS-
PAGE, followed by blotting onto a PVDF membrane (Amersham Biosciences, Otelfingen, 
Switzerland). Expression of MLH1 was detected by the mouse antibody (550838; BD 
Biosciences Pharmingen, Basel, Switzerland). Acetyl-histone H3 (Lys9) and acetyl-histone H4 
(Lys8) were detected by the respective rabbit antibodies (6971, 2594; Cell Signaling; 
BioConcept, Allschwil, Switzerland), as were the rabbit antibodies directed against acetyl-
tubulin (T-6793; Sigma), p21 (2947; Cell Signaling), PARP-1 (9542, Cell Signaling), HDAC-1, 
HDAC-3, HDAC-6 (2062, 2632, 2662; Cell Signaling), HDAC-2 (05-814; Upstate, Lake Placid, 
NY), the multidrug resistance transporters MDR and MRP-1 (sc-13131, sc-18835; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), Bax (2272, Cell Signaling), Bcl-xL (2262, Cell 
Signaling), thioredoxin (2285, Cell Signaling), and the sample loading control /-tubulin 
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(2148, Cell Signaling) or -actin (A-5541; Sigma). The anti-rabbit horseradish peroxidase-
conjugated antibody (7074; Cell Signaling) or the anti-mouse horseradish peroxidase-conjugated 
antibody (M15345; Transduction Laboratories, Lexington, KY) were used as the secondary 
antibodies. Complexes were visualized by enhanced chemiluninescence and autoradiography. 
 
HDAC-2 immunoprecipitation and determination of HDAC activity.  HDAC-2 was 
immunoprecipitated as to the manufacturer’s protocols from nuclear extracts of the TSA-
sensitive MLH1-proficient HCT116ch3 cell line, MLH1-deficient HCT116ch2 cell line, MLH-
proficient HCT116ch3/TSA subline, and the TSA- resistant HCT116ch2/TSA subline using 
Protein A agarose beads (16-266; Upstate) and the immunoprecipitation-qualified HDAC-2 
antibody (05-814; Upstate). Nuclear extracts were produced using the TransFactor Extraction 
Kit as of the manufacturer’s protocol (631921, Clontech, Takara Bio Europe, Saint-Germain-en-
Laye, France). Protein concentrations were determined by the BCA Protein Assay Kit (23227; 
Perbio Science, Lausanne, Switzerland). 
 The HDAC enzymatic activity was determined in nuclear cell extracts using the 
colorimetric HDAC activity assay Kit (ab1432, Abcam) or the fluorometric HDAC assay Kit 
(17-356; Upstate, Lake Placid, NY). Measurements were made with a SpectraFluor Plus Reader 
(TECAN AG, Switzerland). The assays, including all standard assays, were performed 
according to the protocols provided by the manufacturers. The activity assays were performed in 
two independent settings under no-limiting assay conditions. Enzymatic activities were 
standardized (expressed as optical density or counts per amount protein). 
 
Statistical analysis.  The mean ± SD values were calculated. A p value less than 0.05 is 
considered statistically significant (paired, two-tailed Student’s t test). 
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Results 
TSA causes resistance acquisition in the MLH1-deficient HCT116 colon tumor cell line but not 
in the MLH1-proficient HT-29 colon and the HeLa cervical tumor cell lines.  The potential of 
TSA to cause resistance acquisition in two colon tumor cell lines, i.e. HCT116 and HT-29, was 
determined. Clonogenic assay data showed that stepwise exposures to increasing concentrations 
of TSA caused a 3-fold resistance to TSA in the MLH1-deficient (not expressing MLH1 
protein) HCT116 colon tumor cell line but not in the MLH1-proficient (expressing MLH1 
protein) HT-29 colon tumor cell line and in the MLH1-proficient HeLa cervical tumor cell line 
(Fig. 1, Table I). From this, it seemed that TSA caused resistance acquisition only when MLH1 
protein was absent. To confirm this, quasi-isogenic cell lines (derived from the parental MLH1-
deficient HCT116 cell line) either expressing MLH1 protein or lacking MLH1 expression were 
subject to the TSA resistance selection protocol (details described in “Materials and Methods”). 
This protocol produced a 2-fold TSA-resistant subline (HCT116ch2/TSA) only with the MLH1-
deficient (HCT116ch2) but not in the MLH1-proficient (HCT116ch3) cell line (Fig. 2, Table I). 
The presence or absence of MLH1 in all the cell lines and the respective sublines was confirmed 
by immunoblot analysis. The growth rates of the cell lines and the respective sublines were not 
different: 22.6 ± 0.9h (HCT116) vs. 23.1 ± 1.2h (HCT116/TSA), 21.4 ± 1.1h (HCT116ch3) vs. 
22.4 ± 0.9h (HCT116ch3/TSA), 21.6 ± 0.9h (HCT116ch2) vs. 23.3 ± 0.9h (HCT116ch2/TSA). 
TSA-mediated resistance acquisition in the MLH1-deficient sublines can thus not be explained 
by differential growth rates. In addition, acquired TSA resistance was irreversible, as the TSA-
resistant sublines maintained resistance for 5 months of continuous culturing in the absence of 
the TSA selection pressure in the culture medium (30 passages). 
 TSA causes acquisition of irreversible resistance in MLH1-deficient but not in MLH1-
proficient HCT116 colon tumor cells. 
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The TSA-resistant, MLH1-deficient subline fails to accumulate acetylated histones and to induce 
p21 in response to TSA.  As accumulation of acetylated histones and non-histone proteins (e.g. 
tubulin) is a typical response to HDAC inhibitors (22,23), it was determined whether the TSA-
resistant, MLH1-deficient HCT116ch2/TSA subline lacks this response. Immunoblot analysis 
showed that 350 nM TSA produced acetylation of histone H3 and histone H4 in all three TSA-
sensitive cell lines, i.e. the MLH1-proficient HCT116ch3 and HCT116ch3/TSA cells as well as 
the MLH1-deficient HCT116ch2 cells, but not in the TSA-resistant, MLH1-deficient 
HCT116ch2/TSA subline (Fig. 3A). TSA-mediated acetylation of tubulin was detected in all 
four samples (Fig. 3B). Induction of the endogenous cell cycle inhibitor p21 is another typical 
response to HDAC inhibitors (24). It was determined whether acquired TSA resistance in 
MLH1-deficient HCT116ch2/TSA cells correlated with loss of p21 induction. The results 
showed (Fig. 3B) that 350 nM TSA did not induce p21 in these cells, whereas it did in all three 
TSA-sensitive cell lines. 
 Acquired TSA-resistance correlates with loss of histone acetylation and of p21 induction. 
 
TSA-mediated resistance acquisition in the MLH1-deficient subline is associated with loss of 
apoptosis.  It was determined by immunoblot analysis whether loss of apoptosis contributed to 
acquired TSA resistance in the MLH1-deficient subline. The data showed that PARP-1 cleavage 
was strongly reduced in the TSA-resistant subline as compared to all three TSA-sensitive cell 
lines by 350 nM TSA (Fig. 4A), indicating that loss of apoptosis accounted for acquired TSA 
resistance in the MLH1-deficient subline. 
 
TSA-mediated resistance acquisition in the MLH1-deficient subline is not associated with 
expression of multidrug resistance transporters or altered expression of HDACs but with 
reduced expression of Bax.  One reason for acquired TSA resistance and failure in histone 
acetylation and in p21 and apoptosis induction may lie in the reduced availability of TSA in the 
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cells, possibly by expression of the multidrug resistance transporters MDR and MRP-1. 
Immunoblot data (Fig. 5A) showed that these transporters were neither present in untreated cells 
nor was their expression induced by TSA in the TSA-resistant subline. 
 Altered expression of apoptosis regulatory proteins may also account for acquired TSA 
resistance. Immunoblot analysis (Fig. 3B) showed that expression of the pro-papototic Bax was 
decreased in TSA-resistant MLH1-deficient HCT116ch2/TSA subline as compared to the TSA-
sensitive HCT116ch2 cell line, while these expression levels in the TSA-sensitive 
HCT116ch3/TSA subline and the HCT116ch3 cell line were comparable. The expression levels 
of anti-apoptotic Bcl-xL were similar in all four samples, as were those of thioredoxin, a protein 
that scavenges reactive oxygen species that are produced in response to HDAC inhibitors. 
 Overexpression of one or more HDAC, i.e. the targets of HDAC inhibitors, or altered 
HDAC activity may contribute with acquired TSA resistance. However, the class I HDAC-1, 
HDAC-2, and HDAC-3, and the class II HDAC-6 expression was comparable in all four 
samples and the respective expression levels were not affected by 350 nM TSA in the four cell 
lines (Fig. 5B). Overall HDAC activity was comparable in all four samples, and TSA reduced 
the overall activity in all four samples to a similar extent (Fig. 6). The values for a 50% activity 
reduction by TSA in the samples were 7.1±0.6 nM (HCT116ch3), 7.7±1.8 nM 
(HCT116ch3/TSA), 6.9±1.5 nM (HCT116ch2), and 6.5±1.3 nM (HCT116ch2/TSA). Likewise, 
the basal enzymatic activity of individual HDAC-2 (inactivating mutations of which have been 
reported to confer apoptosis resistance, Refs 16,17) in the TSA-resistant sample was not 
different from those in the TSA-sensitive samples, and the HDAC-2 activities in the four 
samples were reduced by TSA to a similar extent. The values for a 50% activity reduction by 
TSA in the samples were 18.8±0.6 nM (HCT116ch3), 18.8±0.4 nM (HCT116ch3/TSA), 
16.5±0.7 nM (HCT116ch2), and 16.3±0.4 nM (HCT116ch2/TSA). 
 Acquired TSA-resistance in the MLH1-deficient HCT116ch2/TSA subline correlates 
with reduced expression of pro-apoptotic Bax, but is neither associated with expression of the 
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MDR and MRP-1 or with overexpression of HDAC-1, HDAC-2, HDAC-3, HDAC-6, and 
thioredoxin, nor with altered HDAC activity. 
 
The TSA-induced resistant subline is cross-resistant to other HDAC-inhibitors but not to non-
HDAC inhibitor- type anticancer agents.  The potential cross-resistance of the TSA-resistant 
MLH1-deficient HCT116ch2/TSA subline to other HDAC inhibitors or to non-HDAC inhibitor-
type anticancer agents was determined. It was found (Fig. 7, Table II) that the TSA-resistant, 
MLH1-deficient subline was cross-resistant to the HDAC inhibitors SAHA and VPA. In 
contrast, the TSA-resistant, MLH1-deficient subline was as sensitive to the non-HDAC 
inhibitor-type docetaxel, doxorubicin, 6-thioguanine, and temozolomide as its TSA-sensitive 
counterpart HCT116ch2. The MLH1-proficient HCT116ch3/TSA subline and HCT116ch3 cell 
line were comparably sensitive to these agents. 
 The TSA-resistant MLH1-deficient HCT116ch2/TSA subline is cross-resistant to SAHA 
and VPA but retains sensitivity against “classic” anticancer agents. 
 
 
 
 
Discussion 
The antineoplastic activity of HDAC inhibitors is a well-known property of these compounds 
(3-7), but recent studies have revealed the potential of HDAC inhibitors such as depsipeptide 
(25,26), VPA and SAHA (1,2) to cause drug resistance acquisition in tumor cells. 
 The present study expands on the issue of resistance acquisition by HDAC inhibitors. 
First, TSA is identified as another HDAC inhibitor which can cause the acquisition of 
irreversible and multidrug resistance transporter-independent resistance in colon tumor cells. 
Second, the herein described resistance acquisition by TSA, in contrast to that by SAHA, is 
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dependent on the absence of MLH1 protein expression, i.e. it did only occur in MLH1-deficient 
colon tumor cells. Third, the TSA-mediated resistance acquisition in these cells strongly 
correlated with loss of accumulation of acetylated histones, loss of p21 induction, and loss of 
apoptosis activation accompanied by reduced Bax expression, three responses normally seen 
with HDAC inhibitors. Fourth, the acquired TSA resistance was associated with cross-resistance 
to other HDAC inhibitors such as SAHA and VPA, but not to non-HDAC inhibitor-type 
anticancer agents such as doxorubicin and docetaxel. From these results, it may be concluded 
that (i) TSA is a potential causative for HDAC inhibitor resistance acquisition and that (ii) 
MLH1 exerts a protective function in colon tumor cells against HDAC inhibitor resistance 
acquisition by TSA. 
 The herein described findings raise some interesting questions. On the one hand, how 
can the presence of MLH1 protein exert its putative protective function against resistance 
acquisition by TSA, how can its absence allow for TSA-mediated resistance acquisition, and 
why does MLH1 expression not protect from resistance acquisition by the structurally related 
SAHA? On the other hand, what is the molecular nature that leads to the loss of accumulation of 
acetylated histones and how does this loss translate into cellular responses eventually leading to 
failure in activating cell death? 
 The finding that TSA-mediated resistance acquisition was seen only in MLH1-deficient 
but not in MLH1-proficient colon tumor cells and hence was dependent on the absence of 
MLH1 protein is with no doubt most notable. It may mean that MLH1, TSA, and HDACs are 
somehow functionally linked. MLH1 is one of at least 5 proteins of the MMR complex that 
functions in the post-replicative processing of base-base mismatches, in the prevention of 
recombination between non-identical DNA sequences, and in mediating the cytotoxic effect of a 
number of anticancer agents including cisplatin, 6-thioguanine, temozolomide, and doxorubicin 
(8-11). Defective MMR confers resistance to these agents (11) and can increase the mutation 
rate in tumor cells (27). TSA has recently been described to promote expression of the MLH1 
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gene (12-14), to be potentially genotoxic due to hyperacetylation of centromers leading to 
aneuploidy, chromosome missegregation, and DNA strand breaks (19,20), and to slow radiation-
induced DNA damage repair process in part by suppressing BRCA1 gene expression (18), a 
protein implicated in DNA strand break repair and in MMR. 
 On this basis, one possible attempt at explaining the observed TSA resistance acquisition 
caused by stepwise exposures to increasing concentrations of TSA in cells with absent MLH1 
protein might be as follows. Hyperacetylation of centromers by high concentrations of TSA may 
cause the formation of DNA strand breaks. The absence of MLH1 protein and hence of MMR 
function may result in insufficient and error-prone repair of these DNA strand breaks. While 
some of these may be tolerated without apparent consequences, some other “severe” DNA 
strand breaks may cause genetic alterations in genes that normally mediate cytotoxic responses 
triggered by HDAC inhibitors. The finding that Bax expression is reduced in the MLH1-
deficient, TSA-resistant cells seems in line with this idea. Conversely, the presence of MLH1 
would allow for detection and proper repair of these DNA strand breaks introduced by high 
concentrations of TSA. This would, in turn, reduce the likelihood for genetic alteration in 
HDAC inhibitor-responsive genes and would ensure that the cell death program triggered by 
HDAC inhibitors is activated and executed. In this way the cells might, despite the selection 
pressure of TSA, maintain their ability to properly respond to HDAC inhibitors. 
 Despite its apparent appeal, this view is rather speculative, and a variety of obscurities 
remain. For instance, despite the putative effect of TSA on MLH1 expression, it is not 
completely understood, why MLH1 should protect from TSA-mediated but not from SAHA-
mediated resistance acquisition as previously reported (1,2), in particular considering the close 
structural relationship between these two pan-HDAC inhibitors. It also seems that the presence 
of any lesion or genetic alteration that would have been introduced by high concentrations of 
TSA does not affect the responsiveness to temozolomide and 6-thioguanine, two cytotoxic 
agents the effect of which depends on functional MMR. 
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 There are several attempts at explaining how loss of accumulation of acetylated histones 
is brought about and how this leads to (undesired) cell survival. One obvious reason is the 
expression of multidrug resistance efflux transporters that reduces the availability of the drug 
within the cell, and another obvious reason is the altered expression of HDACs and/or the 
altered HDAC enzymatic activity. However, expression of MDR or MRP-1, altered expression 
levels of HDAC-1, -2, -3, and -6, or altered overall HDAC activity were not found in the TSA-
resistant subline. In particular, the enzymatic activity of individual HDAC-2, which can be 
abrogated by inactivating mutations in MSI-tumor cells and thus can confer apoptosis resistance 
(16,17), was comparable in the TSA-resistant and the TSA-sensitive cells, indicating that 
acquired TSA resistance cannot be explained by altered HDAC-2 activity. In addition, resistance 
acquisition cannot be explained by differential growth rates of the (original) cell lines from 
which the resistant variants were derived. It also cannot be explained by the presence of the 
extra chromosomes in the chromosome-complemented HCT116ch2 and HCT116ch3 cell lines, 
because resistance acquisition by TSA was also found with the MLH1-deficient HCT116 cell 
line (not chromosome-complemented) but not with the MLH1-proficient HT-29 colon tumor 
cell line. 
 One interesting finding is that the acquired TSA-resistant cells are cross-resistant to other 
HDAC inhibitors but not to “classic” (non-HDAC inhibitor-type) anticancer agents. This 
suggests that this acquired HDAC inhibitor resistance is clearly an issue of defective HDAC 
inhibitor-responsive cytotoxic pathways, while cytotoxic pathways responsive to non-HDAC 
inhibitor-type drugs remain intact in these cells. In clinical terms, this may mean that cells that 
have become resistant during an HDAC inhibitor-based therapy might still be responsive to 
second-line therapy with “classic” anticancer agents. 
 It is to note that, except for the dependence on MLH1-absence, most of the described 
characteristics found with acquired TSA resistance were also found with HDAC inhibitor 
resistance acquisition by SAHA (2), including irreversibility, multidrug resistance transporter-
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independence, association with failure in accumulation of acetylated histones, loss of cell cycle 
checkpoint and apoptosis activation, cross-resistance to other HDAC inhibitors, responsiveness 
retention to “classic” anticancer agents, and the absence of an association with altered HDAC 
expression and enzymatic activities. 
 In conclusion, the present study identifies TSA, besides SAHA and VPA, as another 
potential causative of HDAC inhibitor resistance acquisition in MLH1-deficient colon tumor 
cells, and it reveals a yet unknown function of MLH1 protein in protecting colon tumor cells 
from resistance acquisition by TSA. 
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Table I. Sensitivity of the cell lines and the respective sublines to TSA as expressed by the IC50 
values determined by the clonogenic assay 
Cell line Subline Resistance* (p values) 
HCT116 HCT116/TSA  
7.5 ± 1.4 nM** 20.6 ± 1.4 nM 2.75 (p<0.001) 
   
HT-29 HT-29/TSA  
9.3 ± 0.6 nM 8.7 ± 1.6 nM 0.94 (p=0.673) 
   
HeLa HeLa/TSA  
13.9 ± 1.3 nM 13.4 ± 0.8 nM 0.96 (p=0.595) 
   
HCT116ch2 HCT116ch2/TSA  
8.1 ± 0.4 nM 15.3 ± 2.8 nM 1.89 (p<0.005) 
HCT116ch3 HCT116ch3/TSA  
9.4 ± 3.4 nM 7.4 ± 0.8 nM 0.79 (p=0.273) 
 
*Fold resistance, expressed as the ratio of the IC50 values of the sublines and the respective cell 
lines; **Mean  SD of 4 independent data sets. 
 
 
 
 
Table II. Sensitivity of the MLH1-proficient HCT116ch3 and the MLH1-deficient HCT116ch2 cell lines and the respective HCT116ch3/TSA and 
HCT116ch2/TSA sublines generated by stepwise exposures to TSA as expressed by the IC50 values determined by the clonogenic assay 
HDAC Inhibitor HCT116ch3 HCT116ch3/TSA Resistance*  HCT116ch2 HCT116ch2/TSA Resistance  
SAHA (M) 0.9 ± 0.4** 1.0 ± 0.4 1.11  0.9 ± 0.4 2.4 ± 0.3 2.67*** 
VPA (mM) 2.5 ± 0.2 2.4 ± 0.2 0.97  2.4 ± 0.3 4.7 ± 0.6 1.96*** 
        
Drug HCT116ch3 HCT116ch3/TSA Resistance  HCT116ch2 HCT116ch2/TSA Resistance 
Docetaxel (nM) 0.31 ± 0.03 0.31 ± 0.04 1.00  0.31 ± 0.03 0.31 ± 0.05 1.00 
Doxorubicin (nM) 15.4 ± 0.7 14.6 ± 1.4 0.95  15.6 ± 0.3 13.7 ± 1.2 0.88 
6-Thioguanine (M) 28.0 ± 1.0 25.3 ± 4.0 0.90  80.0 ± 4.0 70.3 ± 2.9 0.88 
Temozolomide (mM) 0.24 ± 0.05 0.23 ± 0.03 0.96  0.50 ± 0.04 0.48 ± 0.06 0.96 
 
*Fold resistance, expressed as the ratio of the IC50 values of the sublines and the respective cell lines; **Mean  SD of at least 3 independent 
experiments; ***p<0.05. 
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Figure legends 
 
Figure 1.  Expression of MLH1 protein and clonogenic survival in response to TSA treatment 
for the colon tumor or cervical tumor cell lines and the respective sublines generated by 
stepwise exposures of these cell lines to increasing concentrations of TSA. A, presence or 
absence of MLH1 expression in the cell lines and the respective sublines (actin is sample 
loading control). B, MLH1-deficient HCT116 colon tumor cell line (square) and MLH1-
deficient HCT116/TSA subline (triangle). C, MLH1-proficient HT-29 colon tumor cell line 
(square) and MLH1-proficient HT-29/TSA subline (triangle). D, MLH1-proficient HeLa 
cervical tumor cell line (square) and MLH1-proficient HeLa/TSA subline (triangle). Each point 
is the mean  SD of 2 independent experiments performed in triplicate cultures. 
Figure 2.  Expression of MLH1 protein (A) and clonogenic survival in response to TSA 
treatment (B) for the chromosome 3-complemented MLH1-proficient HCT116ch3 (black 
square) and the chromosome 2-complemented MLH1-deficient HCT116ch2 (black triangle) 
colon tumor cell lines and the respective sublines HCT116ch3/TSA (white square) and 
HCT116ch2/TSA (white triangle) generated as described by stepwise exposures of these cell 
lines to increasing concentrations of TSA. Actin is sample loading control. Each point is the 
mean  SD of 3 independent experiments performed in triplicate cultures. 
Figure 3.  The acetylation of the histones H3 and H4 (A) and the acetylation of the non-histone 
protein tubulin, the induction of p21, and the expression of Bax, Bcl-xL, and thioredoxin (B) in 
response to 350 nM TSA in the MLH1-proficient HCT116ch3 and the MLH1-deficient 
HCT116ch2 colon tumor cell lines and their respective HCT116ch3/TSA and HCT116ch2/TSA 
sublines. Representative of 2 independent data sets (tubulin is sample loading control). 
Figure 4.  TSA-mediated apoptosis, represented as the cleavage of the 116 kD PARP-1 full 
length precursor into the 86 kD cleaved fragment, in response to treatment with 350 nM TSA in 
21 
22 
the MLH1-proficient HCT116ch3 and the MLH1-deficient HCT116ch2 colon tumor cell lines 
and the respective HCT116ch3/TSA and HCT116ch2/TSA sublines. Representative of 2 
independent data sets with tubulin as sample loading control. 
Figure 5.  Expression of the multidrug resistance transporters MDR and MRP-1 (A) and of the 
histone deacetylases HDAC-1, HDAC-2, HDAC-3, and HDAC-6 (B) in response to 350 nM 
TSA in the MLH1-proficient HCT116ch3 and the MLH1-deficient HCT116ch2 colon tumor cell 
lines and the respective HCT116ch3/TSA and HCT116ch2/TSA sublines. Representative of two 
independent data sets. Positive control lysates for MRP-1 (A549, sc-2413, Santa Cruz 
Biotechnology) and MDR (MES-SA, sc-2284, Santa Cruz Biotechnology) were loaded (center 
lanes in A). Tubulin is sample loading control. 
Figure 6.  Overall HDAC activity expressed as optical density (OD) per mg of nuclear extract 
protein (left panel; colorimetric HDAC activity assay) and individual HDAC-2 activity 
expressed as counts per g HDAC-2 immunoprecipitated from nuclear extracts (right panel, 
fluorometric HDAC assay) obtained from the MLH1-proficient HCT116ch3 and the MLH1-
deficient HCT116ch2 colon tumor cell lines and the respective HCT116ch3/TSA and 
HCT116ch2/TSA sublines treated with various TSA concentrations. Also shown is a positive 
(HeLa nuclear extract) assay control. Mean ± SD of 2 independent data sets. 
Figure 7.  Clonogenic survival of the chromosome 3-complemented MLH1-proficient 
HCT116ch3 (black square) and the chromosome 2-complemented MLH1-deficient HCT116ch2 
(black triangle) cell lines and the respective HCT116ch3/TSA (white square) and 
HCT116ch2/TSA (white triangle) sublines in response to treatment with the HDAC inhibitors 
SAHA (A) and VPA (B) and with the non-HDAC inhibitor-type agents docetaxel (C), 
doxorubicin (D), temozolomide (E), and 6-thioguanine (F). Each point is the mean  SD of 3 
independent experiments performed in triplicate cultures. 
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